Effects of ketamine on the cholecystokinin, somatostatin, substance P, and thyrotropin releasing hormone in discrete regions of rat brain.
Intraperitoneal injection of ketamine (100 mg/kg body weight) significantly reduces the levels of cholecystokinin (CCK), somatostatin (SRIF), and substance P (SP)-like immunoreactivity in various regions of rat brain. No significant change in thyrotropin releasing hormone (TRH)-like immunoreactivity was observed. Neuropeptide systems may be involved in the neuropharmacologic effects of ketamine.
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002766:Cholecystokinin / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism; D007649:Ketamine / Q000494:pharmacology*; D008297:Male; D008636:Mesencephalon / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012249:Rhombencephalon / Q000378:metabolism; D013004:Somatostatin / Q000378:metabolism*; D013373:Substance P / Q000378:metabolism*; D013788:Thalamus / Q000378:metabolism; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism
D013373:Substance P; D013004:Somatostatin; D013973:Thyrotropin-Releasing Hormone; D007649:Ketamine; D002766:Cholecystokinin